LKB1/AMPK/mTOR Signaling Pathway in Non-small-cell Lung Cancer

被引：85
作者：
Han, Dong [1 ]
Li, Shao-Jun [1 ]
Zhu, Yan-Ting [1 ]
Liu, Lu [1 ]
Li, Man-Xiang [1 ]
机构：
[1] Xi An Jiao Tong Univ, Resp Dis Res Ctr, Dept Resp Med, Affiliated Hosp 2,Med Coll, Xian 710049, Peoples R China
来源：
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2013年 / 14卷 / 07期
关键词：
LKB1; AMPK; mTOR; NSCLC; therapeutic target; ACTIVATED PROTEIN-KINASE; IONIZING-RADIATION; LKB1-AMPK PATHWAY; MAMMALIAN TARGET; MTOR; AMPK; GROWTH; LKB1; RAPAMYCIN; PHOSPHORYLATION;
D O I：
10.7314/APJCP.2013.14.7.4033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Links between cancer and metabolism have been suggested for a long time but compelling evidence for this hypothesis came from the recent molecular characterization of the LKB1/AMPK signaling pathway as a tumor suppressor axis. Besides the discovery of somatic mutations in the LKB1 gene in certain type of cancers, a critical emerging point was that the LKB1/AMPK axis remains generally functional and could be stimulated by pharmacological molecules such as metformin in cancer cells. In addition, AMPK plays a central role in the control of cell growth, proliferation and autophagy through the regulation of mTOR activity, which is consistently deregulated in cancer cells. Targeting of AMPK/mTOR is thus an attractive strategy in the development of therapeutic agents against non-small-cell lung cancer (NSCLC). In this review, the LKB1/AMPK/mTOR signaling pathway is described, highlighting its protective role, and opportunities for therapeutic intervention, and clinical trials in NSCLC.
引用
收藏
页码：4033 / 4039
页数：7
相关论文
共 58 条
[1]   Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies [J].
Chapuis, N. ;
Tamburini, J. ;
Green, A. S. ;
Willems, L. ;
Bardet, V. ;
Park, S. ;
Lacombe, C. ;
Mayeux, P. ;
Bouscary, D. .
LEUKEMIA, 2010, 24 (10) :1686-1699
[2]   Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation [J].
Choo, Andrew Y. ;
Yoon, Sang-Oh ;
Kim, Sang Gyun ;
Roux, Philippe P. ;
Blenis, John .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (45) :17414-17419
[3]   Mitochondria as cancer drug targets [J].
Don, AS ;
Hogg, PJ .
TRENDS IN MOLECULAR MEDICINE, 2004, 10 (08) :372-378
[4]   Metformin and reduced risk of cancer in diabetic patients [J].
Evans, JMM ;
Donnelly, LA ;
Emslie-Smith, AM ;
Alessi, DR ;
Morris, AD .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7503) :1304-1305
[5]   Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 [J].
Feldman, Morris E. ;
Apsel, Beth ;
Uotila, Aino ;
Loewith, Robbie ;
Knight, Zachary A. ;
Ruggero, Davide ;
Shokat, Kevan M. .
PLOS BIOLOGY, 2009, 7 (02) :371-383
[6]  
Gansler T, 2010, CA-CANCER J CLIN, V60, P1, DOI [10.3322/caac.20073, 10.3322/caac.20049]
[7]   Defining the role of mTOR in cancer [J].
Guertin, David A. ;
Sabatini, David M. .
CANCER CELL, 2007, 12 (01) :9-22
[8]   mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice [J].
Guertin, David A. ;
Stevens, Deanna M. ;
Saitoh, Maki ;
Kinkel, Stephanie ;
Crosby, Katherine ;
Sheen, Joon-Ho ;
Mullholland, David J. ;
Magnuson, Mark A. ;
Wu, Hong ;
Sabatini, David M. .
CANCER CELL, 2009, 15 (02) :148-159
[9]   AMPK phosphorylation of raptor mediates a metabolic checkpoint [J].
Gwinn, Dana M. ;
Shackelford, David B. ;
Egan, Daniel F. ;
Mihaylova, Maria M. ;
Mery, Annabelle ;
Vasquez, Debbie S. ;
Turk, Benjamin E. ;
Shaw, Reuben J. .
MOLECULAR CELL, 2008, 30 (02) :214-226
[10]   Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity [J].
Hahn-Windgassen, A ;
Nogueira, V ;
Chen, CC ;
Skeen, JE ;
Sonenberg, N ;
Hay, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (37) :32081-32089
123456